<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transplant donor-recipient HBV status</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transplant donor-recipient HBV status</h1>
<div class="graphic"><div class="figure"><div class="ttl">Transplant donor-recipient HBV status</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="15%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Donor HBV status</td> <td class="subtitle1">Recipient HBV serologic status</td> <td class="subtitle1">Kidney transplantation: Whether "to proceed" or "not to proceed"</td> <td class="subtitle1">Antiviral therapy*</td> <td class="subtitle1">Comments</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="4" style="vertical-align: middle;"><strong>Chronic infection</strong></td> <td>No evidence of immunity or infection</td> <td>Avoid transplantation except in exceptional circumstances</td> <td>Yes, if transplanted</td> <td> <ul> <li>May administer hepatitis B immune globulin in addition to antiviral therapy to prevent de novo infection.</li> <li>Recipients should be vaccinated if they have no prior immunity, although the efficacy in eliciting an anti-HBs response is reduced due to the effect of immunosuppressive medications.</li> <li>The optimal duration of antiviral therapy is unknown; we administer therapy for 1 year.</li> </ul> </td> </tr> <tr> <td>Immunity due to vaccination (anti-HBs ≥10 mIU/mL)</td> <td>Yes</td> <td>Yes</td> <td> <ul> <li>Administer antiviral therapy to prevent de novo infection because anti-HBs titer can decrease and become undetectable with immunosuppression.</li> <li>The role of hepatitis B immunoglobulin is uncertain but may be considered perioperatively if the anti-HBs level is below 100 mIU/mL.</li> <li>In recipients with immunity from vaccination, we check the anti-HBs titer prior to discontinuing antiviral therapy and administer a booster dose of vaccine if the titer is &lt;10 mIU/mL.</li> <li>The optimal duration of antiviral therapy is unknown; we administer therapy for 1 year.</li> </ul> </td> </tr> <tr> <td>Prior infection</td> <td>Yes</td> <td>Yes</td> <td> <ul> <li>Recipients who are anti-HBc positive have evidence of prior infection, and HBV reactivation may occur secondary to immunosuppressive therapy. The presence of anti-HBs at time of transplantation may not prevent reactivation, because anti-HBs titer can decrease and become undetectable with immunosuppression.</li> <li>The duration of antiviral therapy can vary. Some centers administer antiviral therapy indefinitely to all recipients with prior HBV. Others discontinue treatment when immunosuppression is reduced to low-dose maintenance level and monitor closely thereafter, unless the patient is receiving immunosuppression with an agent associated with a high risk of HBV reactivation (eg, rituximab).<sup>¶</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Chronic infection</td> <td>Yes</td> <td>Yes</td> <td> <ul> <li>Administer lifelong antiviral therapy to prevent reactivation of HBV secondary to immunosuppressive therapy.<sup>Δ</sup></li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="4" style="vertical-align: middle;"><strong>Prior infection</strong></td> <td>No evidence of immunity or infection</td> <td>Yes</td> <td>No, unless donor has detectable HBV viral load</td> <td> <ul> <li>Recipients should be vaccinated if they have no prior immunity, although the efficacy in eliciting an anti-HBs response is reduced due to the effect of chronic kidney disease and immunosuppressive medications.</li> <li>If antiviral therapy is administered, the optimal duration is unknown; we administer therapy for 1 year.</li> </ul> </td> </tr> <tr> <td>Immunity due to vaccination (anti-HBs ≥10 mIU/mL)</td> <td>Yes</td> <td>No, unless donor has detectable HBV viral load</td> <td> <ul> <li>If antiviral therapy is administered, the optimal duration of antiviral therapy is unknown; we administer therapy for 1 year.</li> <li>In recipients with immunity from vaccination, we check the anti-HBs titer prior to discontinuing antiviral therapy and administer a booster dose of vaccine if the titer is &lt;10 mIU/mL.</li> </ul> </td> </tr> <tr> <td>Prior infection</td> <td>Yes</td> <td>Yes</td> <td> <ul> <li>Recipients who are anti-HBc positive have evidence of prior infection and need antiviral therapy to prevent HBV reactivation secondary to immunosuppressive therapy. The presence of anti-HBs at time of transplantation may not prevent reactivation, because anti-HBs titer can decrease and become undetectable with immunosuppression.</li> <li>The duration of antiviral therapy can vary. Some centers administer antiviral therapy indefinitely to all recipients with prior HBV. Others discontinue treatment when immunosuppression is reduced to low-dose maintenance level and monitor closely thereafter, unless the patient is receiving immunosuppression with an agent associated with a high risk of HBV reactivation (eg, rituximab).<sup>¶</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Chronic infection</td> <td>Yes</td> <td>Yes</td> <td> <ul> <li>Administer life-long antiviral therapy to prevent reactivation of HBV secondary to immunosuppressive therapy.<sup>Δ</sup></li> </ul> </td> </tr> <tr> <td rowspan="4" style="vertical-align: middle;"><strong>No evidence of prior infection</strong><sup>◊</sup></td> <td>No evidence of immunity or infection</td> <td>Yes</td> <td>No</td> <td> </td> </tr> <tr> <td>Immunity due to vaccination</td> <td>Yes</td> <td>No</td> <td> </td> </tr> <tr> <td>Prior infection</td> <td>Yes</td> <td>Yes</td> <td> <ul> <li>Recipients who are anti-HBc positive have evidence of prior infection and may need antiviral therapy to prevent HBV reactivation secondary to immunosuppressive therapy. The presence of anti-HBs at time of transplantation may not prevent reactivation, because anti-HBs titer can decrease and become undetectable with immunosuppression.</li> <li>The duration of antiviral therapy can vary. Some centers administer antiviral therapy indefinitely to all recipients with prior HBV. Others discontinue treatment when immunosuppression is reduced to low-dose maintenance level and monitor closely thereafter, unless the patient is receiving immunosuppression with an agent associated with a high risk of HBV reactivation (eg, rituximab).<sup>¶</sup></li> </ul> </td> </tr> <tr> <td>Chronic infection</td> <td>Yes</td> <td>Yes</td> <td> <ul> <li>Administer life-long antiviral therapy to prevent reactivation of HBV secondary to immunosuppressive therapy.<sup>Δ</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table should be used in conjunction with UpToDate content that discusses HBV infection in kidney transplant recipients.<br/>Definitions:

<ul class="decimal_heading">
<li>No evidence of prior immunity or infection: HBsAg negative, anti-HBc negative, anti-HBs negative</li>
<li>Immunity due to vaccination: HBsAg negative, anti-HBc negative, anti-HBs positive</li>
<li>Chronic HBV infection: HBsAg positive</li>
<li>Prior HBV infection: HBsAg negative, anti-HBc positive</li>
</ul></div><div class="graphic_footnotes">HBV: hepatitis B virus; anti-HBs: hepatitis B surface antibody; mIU: milli-international units; anti-HBc: hepatitis B core antibody; HBsAg: hepatitis B surface antigen.<br/>* Entecavir or tenofovir alafenamide is the preferred antiviral agent.<br/>¶ Some centers may also factor the HBV DNA status of the donor in the decision to administer antiviral therapy.<br/>Δ Refer to UpToDate topics on how to prevent HBV reactivation in patients receiving immunosuppressive therapy.<br/><span class="lozenge">◊</span> If the donor is anti-HBc negative and anti-HBs positive, the donor is immune because of vaccination, not past infection.</div><div id="graphicVersion">Graphic 119670 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
